Research programme: Merkel cell carcinoma therapies - Vironika
Latest Information Update: 28 Aug 2020
At a glance
- Originator Vironika
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Viral protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Merkel cell carcinoma
Highest Development Phases
- No development reported Merkel cell carcinoma
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Merkel cell carcinoma in USA
- 18 Jul 2016 Research programme: Merkel cell carcinoma therapies - Vironika is available for licensing as of 18 Jul 2016. http://www.vironika.com/Vironika/
- 18 Jul 2016 Early research in Merkel cell carcinoma in USA (unspecified route)
Development Overview
Introduction
Vironika is developing small-molecule viral protein inhibitors for the treatment of Merkel cell carcinoma caused by Merkel cell polyomavirus. According to the company pipeline, as of July 2016, development is at the early research (target identification) stage in the US.
The company is seeking a partner to accelerate product development and commercialisation and to facilitate the sales and distribution of its future products.
As at August 2020, no recent reports of development had been identified for research development in Merkel cell carcinoma in USA.
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class Antineoplastics, Antivirals, Small molecules
- Target Viral protein
- Mechanism of Action Viral protein inhibitors
-
WHO ATC code
L01 (Antineoplastic Agents)
-
EPhMRA code
L1 (Antineoplastics)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Merkel cell carcinoma | - | - | No development reported (Research) | USA | unspecified / unspecified | Vironika | 28 Aug 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Vironika | Originator | USA |
| Vironika | Owner | USA |
Licensing Availability
| Licensing Organisation | Available Indication | Available Phase | Region | Date |
|---|---|---|---|---|
| Vironika | Merkel cell carcinoma | Unspecified | - | 18 Jul 2016 |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Aug 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Merkel cell carcinoma in USA Updated 28 Aug 2020 |
| 18 Jul 2016 | Licensing Status | Research programme: Merkel cell carcinoma therapies - Vironika is available for licensing as of 18 Jul 2016. http://www.vironika.com/Vironika/ Updated 18 Jul 2016 |
| 18 Jul 2016 | Phase Change | Early research in Merkel cell carcinoma in USA (unspecified route) Updated 18 Jul 2016 |
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG